Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$218.5M raised · US$19 a share · TD Cowen +5 Dealers: TD Cowen (lead), Evercore ISI (co-lead), Guggenheim Securities (co-lead), LifeSci Capital (co-lead), Oppenheimer & Co. (co-lead), H.C. Wainwright & Co. (co-lead) | Nov 20, 2025 |
| Private placement of common stock and pre-funded warrants Announced: about US$250M · US$9.08 a share · Jefferies +6 Dealers: Jefferies (lead), J.P. Morgan, Goldman Sachs & Co. LLC, Citigroup, LifeSci Capital, Oppenheimer & Co., H.C. Wainwright & Co. Buyers: Adage Capital Partners LP; Bain Capital Life Sciences; BVF Partners L.P.; Driehaus Capital Management; Janus Henderson Investors; Paradigm BioCapital Advisors; Wellington Management; Woodline Partners LP Use of proceeds: Fund the OPERA-02 trial, the Phase 1/2 study of OP-3136, the ongoing Phase 3 OPERA-01 trial, working capital and general corporate purposes | Dec 2, 2024 |